Seizure: European Journal of Epilepsy
Volume 19, Issue 3 , Pages 140-146 , April 2010

POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders

  • Russell P. Saneto

      Affiliations

    • Division of Pediatric Neurology, Seattle Children's Hospital/University of Washington, Seattle, WA 98105, USA
    • These authors contributed equally.
    • ,
  • Inn-Chi Lee

      Affiliations

    • Department of Pediatrics, School of Medicine, Chung Shan Medical University, Taichung, Taiwan
    • Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, NAB 2015, Houston, TX 77030, USA
    • These authors contributed equally.
    • ,
  • Mary Kay Koenig

      Affiliations

    • Division of Child & Adolescent Neurology, University of Texas Medical School at Houston, TX 77030, USA
    • ,
  • Xinhua Bao

      Affiliations

    • Department of Pediatrics, Peking University First Hospital, Beijing 100034, China
    • ,
  • Shao-Wen Weng

      Affiliations

    • Department of Internal Medicine, Chang Gung Memorial Hospital, Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan
    • Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, NAB 2015, Houston, TX 77030, USA
    • ,
  • Robert K. Naviaux

      Affiliations

    • Departments of Medicine and Pediatrics, University of California San Diego, La Jolla, CA, USA
    • ,
  • Lee-Jun C. Wong

      Affiliations

    • Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, NAB 2015, Houston, TX 77030, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 713 798 1940; fax: +1 713 798 8937.

Received 28 October 2009 ,Revised 31 December 2009 ,Accepted 7 January 2010.

References 

  1. Alpers BJ. Diffuse progressive degeneration of the gray matter of the cerebrum. Archives of Neurology and Psychiatry. 1931;25:469–505
  2. Huttenlocher PR, Solitare GB, Adams G. Infantile diffuse cerebral degeneration with hepatic cirrhosis. Archives of Neurology. 1976;33:186–192
  3. Bicknese AR, May W, Hickey WF, Dodson WE. Early childhood hepatocerebral degeneration misdiagnosed as valproate hepatotoxicity. Annals of Neurology. 1992;32:767–775
  4. Naviaux RK, Nguyen KV. POLG mutations associated with Alpers’ syndrome and mitochondrial DNA depletion. Annals of Neurology. 2004;55:706–712
  5. McFarland R, Hudson G, Taylor RW, Green SH, Hodges S, McKiernan PJ, et al. Reversible valproate hepatotoxicity due to mutations in mitochondrial DNA polymerase gamma (POLG1). Archives of Disease in Childhood. 2008;93:151–153
  6. Spinazzola A, Viscomi C, Fernandez-Vizarra E, Carrara F, D’Adamo P, Calvo S, et al. MPV17 encodes an inner mitochondrial membrane protein and is mutated in infantile hepatic mitochondrial DNA depletion. Nature Genetics. 2006;38:570–575
  7. Mandel H, Szargel R, Labay V, Elpeleg O, Saada A, Shalata A, et al. The deoxyguanosine kinase gene is mutated in individuals with depleted hepatocerebral mitochondrial DNA. Nature Genetics. 2001;29:337–341
  8. Hakonen AH, Isohanni P, Paetau A, Herva R, Suomalainen A, Lonnqvist T. Recessive Twinkle mutations in early onset encepalopathy with mtDNA depletion. Brain. 2007;130:3032–3040
  9. Yakubovskaya E, Lukin M, Chen Z, Berriman J, Wall JS, Kobayashi R, et al. The EM structure of human DNA polymerase gamma reveals a localized contact between the catalytic and accessory subunits. EMBO Journal. 2007;26:4283–4291
  10. Carrodeguas JA, Theis K, Bogenhagen DF, Kisker C. Crystal structure and deletion analysis show that the accessory subunit of mammalian DNA polymerase gamma, Pol gamma B, functions as a homodimer. Molecular Cell. 2001;7:43–54
  11. Wong L-J, Naviaux RK, Brunetti-Pierri N, Zhang Q, Schmitt ES, Truong C, et al. Molecular and clinical genetics of mitochondrial diseases due to POLG mutations. Human Mutation. 2008;29:E150–172
  12. Bao X, Wu Y, Wong L-JC, Zhang Y, Xiong H, Chou P-C, et al. Alpers syndrome with prominent white matter changes. Brain and Development. 2008;30:295–300
  13. Castro-Gabo M, Gonzalez-Conde V, Fernandez-Seara MJ, Rodrigo-Saez E, Fernandex-Cebrian S, Alonso-Martin A, et al. Early mitochondrial encephalomyopathy due to complex IV deficiency consistent with Alpers–Huttenlocker syndrome report of two cases. Review Neurology. 1999;29:912–917
  14. Dreifuss FE, Santilli N, Langer DH, Sweeney KP, Moline KA, Menander KB. Valproic acid hepatic fatalities: a retrospective review. Neurology. 1987;37:379–385
  15. Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalized and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369:1016–1026
  16. French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, et al. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the therapeutics and technology assessment subcommittee and quality standards subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2004;62:1252–1260
  17. Coppola G. Treatment of partial seizures in childhood: an overview. CNS Drugs. 2004;18:133–156
  18. Saneto RP, Kotagal P, Rothner AD, Baker J, Kotagal LL. Valproic acid use in pedatric partial epilepsy after initial medication failure. Journal of Pediatric Neurology. 2004;2:199–203
  19. Dean JC, Penry JK. Valproate monotherapy in 30 patients with partial seizures. Epilepsia. 1988;29:140–144
  20. Berkovic SF. Progressive myoclonus epilepsies. In:  Pellock JM,  Dodson WE,  Bourgeois BFD editor. Pediatric epilepsy diagnosis and therapy. 2nd ed.. New York: Demos Medical Publishing; 2001;p. 233–242
  21. Wolf NI, Rahman S, Schmitt B, Taanman J-W, Duncan AJ, Harting I, et al. Status epilepticus in children with Alpers’ disease caused by POLG1 mutations: EEG and MRI findings. Epilepsia. 2009;50:1596–1607
  22. Chinnery PF, Zeviani M. 155th ENMC workshop: polymerase gamma and disorders of mitochondrial DNA synthesis, 21–23 September 2007, Naarden, The Netherlands. Neuromuscular Disorders. 2008;18:259–267
  23. Engelsen BA, Bernt A, Tzoulis C, Karlsen B, Lillebo A, Laegreid LM, et al. POLG1 mutations cause a syndromic epilepsy with occipital lobe predilection. Brain. 2008;131:818–828
  24. Uusimaa J, Hinttala R, Rantala H, Paivarinta M, Herva R, Roytta M, et al. Homozygous W748S mutation in the POLG1 gene in patients with juvenile-onset Alpers syndrome and status epilepticus. Epilepsia. 2008;49:1038–1045
  25. Wiltshire E, Davidzon G, DiMauro S, Akman HO, Sadleir L, Haas L, et al. Juvenile Alpers disease. Archives of Neurology. 2008;65:121–124
  26. Galimberti CA, Diegoli M, Sartori I, Uggetti C, Brega A, Tartara A, et al. Brain pseudoatrophy and mental regression on valproate and a mitochondrial DNA mutation. Neurology. 2006;67:1715–1717
  27. Lam CW, Lau CH, Williams JC, Chan YW, Wong L-JC. Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) triggered by valproate therapy. European Journal of Pediatrics. 1997;156:562–564
  28. Tulinius MH, Hagne I. EEG findings in children and adolescents with mitochondrial encephalomyopathies: a study of 25 cases. Brain and Development. 1991;13:167–173
  29. Boyd SG, Harden A, Egger J, Pampliglione G. Progressive neuronal degeneration of childhood with liver disease (“Alpers’ disease”): characteristic neurophysiological features. Neuropediatrics. 1986;17:75–80
  30. Saneto RP, Cohen BH, Hoppel CL. Epilepsia partialis continua associated with mitochondrial electron transport chain dysfunction. Annals of Neurology. 2002;52(Suppl. 1):S150
  31. Elia M, Musumeci SA, Ferri R, Colamaria V, Azan G, Greco D, et al. Leigh syndrome and partial defect of cytochrome c oxidase associated with epilepsia partialis continua. Brain and Development. 1996;18:207–211
  32. Schuelke M, Bakker M, Stoltenburg G, Sperner J, von Voers A. Epilepsia partialis continua associated with a homoplasmic mitochondrial tRNA Ser(UCN) mutation. Annals of Neurology. 1998;44:700–704
  33. Saneto RP, Friedman S, Shaw DWW. Neuroimaging and mitochondrial disease. Mitochondrion. 2008;8:396–413
  34. Haas RH, Parika S, Falk MJ, Saneto RP, Wolf NI, Darin N, et al. The in-depth evaluation of suspected mitochondrial disease: The Mitochondrial Medicine Society's Committee on diagnosis. Molecular Genetics and Metabolism. 2008;94:16–37
  35. Haas RH, Parikh S, Falk MJ, Saneto RP, Wolf N, Darin N, et al. Mitochondrial disease: a practical approach for primary care physicians. Pediatrics. 2007;120:1326–1333
  36. Stewart JD, Tennant S, Powell H, Pyle A, Blakely EL, He L, et al. Novel POLG1 mutations associated with neuromuscular and liver phenotype in adults and children. Journal of Medical Genetics. 2009;46:209–214

PII: S1059-1311(10)00003-8

doi: 10.1016/j.seizure.2010.01.002

Seizure: European Journal of Epilepsy
Volume 19, Issue 3 , Pages 140-146 , April 2010

Article Tools

* Image Usage & Resolution